Drugs / GSK2983559
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03358407 | Jan 2018 → Feb 2019 | inflammatory bowel disease | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2983559 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03358407 ↗ |
| Action | Inhibit | “a selective receptor interacting protein 2 (RIP2) kinase inhibitor” NCT03358407 ↗ |
| Route | Oral | “oral capsules” NCT03358407 ↗ |